Never let it be said that Valeant (NYSE: VRX) management is shy about doing deals. With a roster of past deals including Biovail, Cephalon, OraPharma, and Medicis, Valeant claims that better than 80% of its deals have attained the 20% internal return target it uses to evaluate potential transactions. If rumors out Friday prove true, Valeant is about to bag its biggest target yet in what would be a particularly bold move.
California medical device maker Bausch + Lomb announced today that it won FDA approval for its 1st-of-its-kind Trulign Toric intraocular lens.
The regulatory approval grants B+L permission to market the lens in the U.S. for treatment of astigmatism as well as improving vision across a natural range of focus without the use of glasses.
Bausch + Lomb won new CE Mark approvals for its Victus laser platform, allowing the device maker to market the system for additional uses during cataract surgery.
In additional to corneal incision, European regulators approved 2 additional indications for Victus, green-lighting the system for use during full corneal transplant, or penetrating keratoplasty, and for incisions performed during device implants into the eye.
An FDA advisory panel agreed on April 8 to recommend approval of Bausch + Lomb’s 1st-of-its-kind intraocular lens for patients who have had a cataract removed and would like to, without glasses, have improved distance vision and reduced residual refractive cylinder.
An FDA advisory panel agreed today to recommend that the federal watchdog agency approve Bausch + Lomb’s first-of-a-kind intraocular lens for patients who have had a cataract removed and would like to, without glasses, have improved distance vision and reduced residual refractive cylinder.
The panel voted 10-0 with 2 abstentions that Bausch + Lomb proved the Trulign Toric posterior chamber intraocular lens is safe; 10-1 with 1 abstention that the device is effective; and 10-1 with 1 abstention that its benefits outweight its risks.
Eye care giant Bausch + Lomb won a date with the FDA for review of its Trulign Toric intraocular lens for improving vision in patient who have undergone cataract surgery.
On April 8, 2012, the FDA’s Ophthalmic Devices Panel will review clinical data and cast a vote on the Trulign Toric implant in treatment of patients with vision impairment as a result of aphakia and postoperative refractive astigmatism.
Second Sight Medical registered with the SEC for a $25 million offering of equity, debt, options and warrants as it waits for the FDA to decide whether to give the green light to its "bionic eye" retinal implant.
The Sylmar, Calif.-based medical device company filed with the securities watchdog agency yesterday, saying it has yet to sell any of the $1,000 shares in the offering.
Eye care giant Bausch + Lomb received the FDA’s highest-risk classification for a recall of several lots of sterile cannulas after a few patients were seriously injured with the small tubes detached from syringes during injection.
The FDA gave the recall Class I status, generally reserved for recalls which "involve situations in which there is a reasonable probability that use of these products will cause serious adverse health consequences or death," according to the FDA notice.
Marlborough, Mass.-based medical device company Boston Scientific is 1 of the Emerald Isle’s largest employers, with a 4,500-employee workforce there.
If Robert Grant is successful – a good bet, judging by his track record – 1 day his new venture, private equity firm Strathspey Crown, will be known as a leader in the nascent field of "lifestyle medicine."
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.